Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Pharmacokinetics and Pharmacodynamics

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery
Deborah Knoerzer
1BioMed Valley Discoveries, Kansas City, MO;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Teresk
1BioMed Valley Discoveries, Kansas City, MO;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Krutzik
2Primity Bio, Fremont, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika O’Donnell
2Primity Bio, Fremont, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary DeCrescenzo
1BioMed Valley Discoveries, Kansas City, MO;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Welsch
1BioMed Valley Discoveries, Kansas City, MO;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Emery
1BioMed Valley Discoveries, Kansas City, MO;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-17-B085 Published January 2018
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA

Abstract

The phosphoinositide 3-kinase (PI3K) family of enzymes play a pivotal role in controlling vital cellular functions, including proliferation, motility, glucose metabolism, and survival. The PI3Kγ isoform has been shown to play an important role in immune cell migration and function in the tumor microenvironment. BVD-723 is a potent and selective small-molecule inhibitor of the PI3Kγ isoform (PI3K γ/α/β/δ Ki = 8/280/220/160 nM). AKT, a serine/threonine protein kinase, is a downstream effector of PI3K. AKT phosphorylation was therefore chosen as a PD marker to demonstrate BVD-723 activity. Here we describe the PK/PD relationship from a single-day, oral, multi-dose level, multi-timepoint study in Balb/c mice. The PD assay, utilizing phospho flow cytometry, measured the ability of BVD-723 to attenuate AKT phosphorylation at the S473 residue in response to extracellular ligands in primary cell subsets that included monocytes, T cells, and B cells. Initial work identified CCL2 and CXCL12, which are thought to signal primarily through PI3Kγ, as ligands that induced robust pAKT signal in both human and murine monocytes. LPS, which is thought to signal primarily through PI3Kδ, was used to assess isoform selectivity in this assay. BVD-723 was administered as a single oral dose (0.5, 1, 3, 5, 10, 30, or 100 mg/kg) to Balb/c female mice. Blood was collected via terminal draw from 3 animals per dose group and per timepoint (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours) and was split into two samples. The first sample was processed to plasma and BVD-723 levels measured using LC-MS/MS assay. The second whole blood sample was analyzed for pAKT following ex vivo stimulation. PK analysis of each dose demonstrated a Tmax between 2-6 hours and a t1/2 of 4-5 hours. The Cmax levels for each dose of 0.5, 1, 3, 5, 10, 30, and 100 mg/kg were 218, 577, 2050, 3670, 9130, 23200, and 29300 ng/ml, respectively, and the AUC0-24 values were 1.8, 5, 21, 38.2, 107, 318, and 519 µg*hr/ml, respectively. The PD assay demonstrated a clear dose- and time-dependent inhibition of AKT phosphorylation in monocytes downstream of CCL2 and CXCL12 stimulation but not LPS stimulation. Consistent with the PK data, a peak inhibition of pAKT signal occurred between 2-4 hours post dose. The CXCL12-induced AKT phosphorylation in monocytes was robustly inhibited for 24 hours at 30 mg/kg and 100 mg/kg. Overall, the PD results showed clear selectivity of BVD-723 for PI3Kγ inhibition in monocytes, with no inhibition of PI3Kδ. Additional ex vivo studies in blood were conducted utilizing this PD assay comparing other PI3K isoform selective inhibitors to BVD-723. These data provide a solid PK/PD relationship, providing guidance for continued development of BVD-723 for oncology.

Citation Format: Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch, Caroline Emery. Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B085.

  • ©2018 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 17 (1 Supplement)
January 2018
Volume 17, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor
Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery
Mol Cancer Ther January 1 2018 (17) (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor
Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery
Mol Cancer Ther January 1 2018 (17) (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Pharmacokinetics and Pharmacodynamics

  • Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
  • Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
  • Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
Show more Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts

  • Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
  • Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
  • Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
Show more Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement